The Globe and Mail reports in its Tuesday, March 12, edition that Leede Jones Gable analyst Douglas Loe is sticking with his "buy" recommendation for Extendicare. The Globe's Darcy Keith writes in the Eye On Equities column that Mr. Loe boosted his share target by $1.25 to $8.50. Mr. Loe notes that Extendicare enjoyed strong adjusted earnings and margin fundamentals across all its elder-care service divisions in its fourth quarter. Mr. Loe says in a note: "The quarter revealed sequential operating income and margin strength across all elder-care service divisions and doing so without any of the supplemental pandemic-related funding that offset pandemic-related costs [during prior periods]. ... Virtually all operating metrics were up sequentially in the quarter, with funding environment in both nursing care and home healthcare expected to improve F2024/25 profitability even further." Mr. Loe adds that Extendicare's adjusted funds from operations now "comfortably" fuels its quarterly dividend. The Globe reported on March 7, 2023, that RBC rated Extendicare "sector perform." It was then worth $6.51. The Globe reported on May 10, 2023, that National Bank rated Extendicare "sector perform." It was then worth $7.